natgillin/translations-raw huggingface dataset:
Movymia contains the active substance teriparatide that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation. 
Zdravilo Movymia vsebuje učinkovino teriparatid, ki jo uporabljamo za krepitev kosti in zmanjšanje tveganja za zlome s spodbujanjem tvorjenja kostnine.
Posology The recommended dose of Movymia is 20 micrograms administered once daily. 
Odmerjanje Priporočeni odmerek zdravila Movymia je 20 mikrogramov enkrat dnevno.
If you forget an injection or cannot use your medicine at your usual time, inject it as soon as possible on that day. 
Če ste pozabili ali ne morete uporabiti svojega zdravila ob vaši običajni uri, si ga injicirajte, kakor hitro morete, še ta dan. Ne uporabite dvojnega odmerka, če ste pozabili uporabiti prejšnji odmerek.
What Movymia is and what it is used for What you need to know before you use Movymia How to use Movymia 
Kaj je zdravilo Movymia in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Movymia Kako uporabljati zdravilo Movymia Možni neželeni učinki
• Put the Movymia Pen, with the cartridge inserted, back into the refrigerator between 2 and 8 °C immediately after use. 
• Takoj po uporabi shranite Movymia Pen z vstavljenim vložkom nazaj v hladilnik na temperaturo med 2 in 8° C.
Before disposing of the Movymia Pen always remove the pen needle and the cartridge. 
Preden odvržete Movymia Pen, vedno odstranite iglo peresnika in vložek.
The amount of Movymia left in the cartridge is less than 80 microlitres. 
Količina zdravila Movymia v vložku je manjša od 80 mikrolitrov.
If you stop using Movymia 
Če ste prenehali uporabljati zdravilo Movymia
If, by mistake, you have used more Movymia than you should, contact your doctor or pharmacist. 
Če ste uporabili večji odmerek zdravila Movymia, kot bi smeli Če ste pomotoma uporabili višji odmerek zdravila Movymia, kot bi smeli, pokličite svojega zdravnika ali farmacevta.
Instructions for use Movymia Pen 
Navodila za uporabo Movymia Pen
Other common side effects (affecting up to 1 in 10 people) include feeling sick, headache and dizziness. 
Drugi pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov) vključujejo siljenje na bruhanje, glavobol in omotico.
1 Movymia cartridge 1 Movymia Pen 
1 vložek Movymia 1 peresnik Movymia Pen
You should inject Movymia shortly after you take the pen with inserted cartridge out of the refrigerator. 
Zdravilo Movymia si vbrizgajte kmalu po tem, ko vzamete peresnik z vstavljenim vložkom iz hladilnika.
EU/1/16/1161/001 [1 cartridge] EU/1/16/1161/002 [3 cartridges] EU/1/16/1161/003 [cartridge and pen pack] 
EU/1/16/1161/001 [1 vložek] EU/1/16/1161/002 [3 vložki] EU/1/16/1161/003 [komplet vložka in peresnika]
EU/1/16/1161/001 [1 cartridge] EU/1/16/1161/002 [3 cartridges] 
EU/1/16/1161/001 [1 vložek] EU/1/16/1161/002 [3 vložki]
3 mL cartridge (siliconised Type I glass), with a plunger stopper (bromobutyl) and disc seal (aluminium and rubber liner seals), packed in a plastic tray sealed with lid foil and packed in a carton. 
3-mililitrski vložek (silikonizirano steklo tipa I) z batom, zaporko (bromobutil) in zaporno ploščico (aluminij in gumijasta obložna tesnila), pakiran na plastičen podstavek s tesnilnim pokrovom iz folije in pakiran v škatli.
If still no medicine is expelled, do not use this pen; contact customer service. 
Če še vedno iz igle ne pride zdravilo, peresnika ne uporabljajte; kontaktirajte podporo uporabnikom.
Women of childbearing potential / Contraception in females Women of childbearing potential should use effective methods of contraception during use of teriparatide. 
Ženske, ki bi lahko zanosile/Kontracepcija za ženske Ženske, ki bi lahko zanosile, morajo med uporabo teriparatida uporabljati učinkovito metodo kontracepcije.
Use only with Movymia Pen. 
Uporabljati le s peresnik Movymia Pen.
For those subjects who had baseline and follow-up spine radiographs, the incidence of new vertebral fractures was 28/516 (5.4%) in teriparatide- and 64/533 (12.0%) in risedronate-treated patients, relative risk (95% CI) = 0.44 (0.29-0.68), p<0.0001. 
Pri bolnicah, pri katerih so opravili radiografijo osnovnega stanja in radiografijo za spremljanje stanja, je bila incidenca novih zlomov vretenc 28/516 (5,4 %) v skupini s teriparatidom in 64/533 (12,0 %) pri bolnicah, zdravljenih z rizedronatom, relativno tveganje (95-odstotni IZ) = 0,44 (0,29-0,68), p < 0,0001.
Preparing the pen for use - To ensure the correct administration of Movymia always read the Instructions for Use of Movymia Pen, which is included in the carton of the pen. 
Priprava peresnika za uporabo - Da boste zagotovili pravilno dajanje zdravila Movymia, vedno preberite Navodila za uporabo perensnika Movymia Pen, ki so priložena v škatli s peresnikom.
How to use Movymia 
Kako uporabljati zdravilo Movymia
Insert a new Movymia cartridge into the cartridge holder, with the metal crimped cap of the cartridge first. 
Vstavite nov vložek Movymia v nosilec vložka tako, da najprej vstavite kovinsko pokrivno kapico vložka.
• Transport and store the Movymia Pen with inserted cartridge at temperatures specified in the Movymia package leaflet, provided separately. 
• Movymia Pen z vstavljenim vložkom prenašajte in shranjujte pri temperaturah, navedenih v navodilu za uporabo zdravila Movymia, ki so priložena ločeno.
If you are a woman of child-bearing potential, you should use effective methods of contraception during use of Movymia. 
Če ste ženska, ki bi lahko zanosila, morate med uporabo zdravila Movymia uporabljati učinkovito metodo kontracepcije.
Movymia is used to treat osteoporosis in adults. 
Zdravilo Movymia uporabljamo za zdravljenje osteoporoze pri odraslih.
Use a new needle for your injection on the following day. 
Naslednji dan uporabite novo iglo za injiciranje.
EU/1/16/1161/003 [cartridge and pen pack] 
EU/1/16/1161/003 [komplet vložka in peresnika]
Before inserting a cartridge in Movymia Pen write down the batch (Lot) number of the cartridge and its first injection date on a calendar. 
Preden vstavite vložek v peresnik Movymia Pen, morate na koledar zabeležiti številko serije (Lot) vložka in datum prvega injiciranja.
• Turn the dose knob clockwise until you see a droplet sign on the dose display. 
• Gumb za odmerjanje obračajte v smeri urinega kazalca, dokler na prikazu odmerka ne vidite znaka kapljice.
It should be administered exclusively with the Movymia Pen reusable, multidose medicine delivery system and the injection needles which are listed as compatible in the instructions which are provided with the pen. 
Zdravilo se daje izključno s sistemom Movymia Pen za dostavo zdravila v več odmerkih in za večkratno uporabo ter z injekcijskimi iglami, ki so navedene kot združljive v navodilih, priloženih peresniku.
However, for treatment initiation a cartridge and pen pack should be used containing one carton of Movymia cartridge and one carton of Movymia Pen. 
Vendar je potrebno za začetek zdravljenja uporabiti komplet vložka in peresnika, ki vsebuje eno škatlo vložka Movymia in eno škatlo s Movymia Pen peresnikom.
Movymia 20 micrograms/80 microliters solution for injection: 1 or 3 cartridge(s) packed in a plastic tray sealed with lid foil and packed in a carton. 
Movymia 20 mikrogramov/80 mikrolitrov raztopina za injiciranje: 1 ali 3 vložki, pakirani na plastičen podstavek s tesnilnim pokrovom iz folije in pakirani v škatli.
Talk to your doctor before or while using Movymia: 
Pred ali med uporabo zdravila Movymia se posvetujte s svojim zdravnikom:
Movymia cartridge and pen pack: 1 Movymia cartridge packed in a plastic tray sealed with lid foil and packed in a carton and 1 Movymia Pen packed into a separate carton. 
Movymia komplet vložka in peresnika: 1 vložek Movymia pakiran na plastičen podstavek s tesnilnim pokrovom iz folije in pakiran v škatli ter 1 pripomoček Movymia Pen v ločeni škatli.
Movymia is contraindicated for use during breast-feeding. 
Zdravilo Movymia je med dojenjem kontraindicirano.
Movymia can be injected at meal times. 
Zdravilo Movymia si lahko injicirate v času obrokov.
Movymia cartridges are to be used in Movymia Pen reusable, multidose pen device exclusively and must not be used with any other pen. 
Vložki zdravila Movymia se uporabljajo izključno s peresnikom Movymia Pen za dostavo več odmerkov in za večkratno uporabo in se jih ne sme uporabljati z nobenim drugim peresnikom.
The reusable fixed dose pen is designed for easy administration of Movymia to treat osteoporosis. 
Peresnik za večkratno uporabo je namenjen enostavni uporabi nespremenljivih odmerkov zdravila Movymia za zdravljenje osteoporoze.
If pregnancy occurs, Movymia should be discontinued. 
Če zanosijo, mora biti zdravilo Movymia ukinjeno.
Read both the package leaflet of Movymia cartridge and the instructions for use of the Movymia Pen before use. 
Pred uporabo preberite priloženo navodilo za vložek Movymia in navodila za uporabo peresnika Movymia Pen.
Do not use Movymia if solid particles appear or if the solution is cloudy or coloured. 
Ne uporabljajte zdravila Movymia, če opazite trdne delce v raztopini ali je raztopina videti motna ali obarvana.
Movymia should not be used if the solution is cloudy, coloured or contains visible particles. 
Zdravila Movymia ne smete uporabiti, če je raztopina motna, obarvana ali vsebuje vidne trdne delce.
Movymia Pen parts 
Movymia Pen deli
Movymia 20 micrograms/80 microliters solution for injection: 1 or 3 cartridges. 
Movymia 20 mikrogramov/80 mikrolitrov raztopina za injiciranje: 1 ali 3 vložki.
Movymia contains a clear and colourless solution. 
Zdravilo Movymia je brezbarvna in bistra raztopina.
The pen is customised for use with Movymia only. 
Peresnik je prilagojen izključno za uporabo z zdravilom Movymia.
The date of first injection should also be recorded on the outer carton of Movymia (see the provided space on the box: {First use:}) (see section 3. 
Datum prvega injiciranja morate zabeležiti tudi na zunanjo ovojnino zdravila Movymia (glejte za to namenjeno okence na škatli {Prva uporaba:}) (glejte poglavje 3).
Movymia contains sodium 
Zdravilo Movymia vsebuje natrij
The incidence of vertebral fractures was assessed in 448 placebo and 444 teriparatide patients who had baseline and follow-up spine radiographs. 
Okrajšave: N = število bolnikov, naključno vključenih v vsako skupino zdravljenja; IZ = interval zaupanja Incidenca vretenčnih zlomov je bila ocenjena pri 448 bolnikih, ki so prejemali placebo in 444 bolnikih, ki so prejemali teriparatid in so imeli radiografijo osnovnega stanja in ponovne ocene hrbtenice.
Do not drop your pen and avoid knocking it against hard surfaces. 
Ne mečite peresnika in izogibajte se trkom s trdimi površinami.
The cartridge and pen pack should be used for treatment initiation. 
Komplet vložka in peresnika se uporablja samo za začetno zdravljenje.
The date of first injection should also be recorded on the outer carton of Movymia (see the provided space on the box: {First use:}). 
Datum prvega injiciranja mora biti zabeležen tudi na zunanji ovojnini zdravila Movymia (glejte za to namenjeno okence na škatli {Prva uporaba:}).
Movymia cartridges are designed to be used only with the Movymia Pen reusable, multidose delivery system and compatible pen needles. 
Vložki zdravila Movymia so zasnovani izključno za uporabo z iglami, združljivimi s peresnikom Movymia Pen za dostavo več odmerkov in za večkratno uporabo.
• increase in blood uric acid level • increase in an enzyme called alkaline phosphatase. 
• zvišanje encima, imenovanega alkalna fosfataza
Fatigue, chest pain, asthenia, mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritus and minor bleeding at injection site 
Splošne težave in spremembe na mestu aplikacije utrujenost, bolečina v prsnem košu, astenija, blagi in prehodni učinki na mestu injiciranja, vključno z bolečino, oteklino, rdečino, omejeno podplutbo, srbenjem in manjšo krvavitvijo na mestu injiciranja rdečina na mestu injiciranja, reakcija na mestu injiciranja možne alergijske reakcije kmalu po injiciranju: akutna dispneja, edem ust/obraza, generalizirana koprivnica, bolečina v prsnem košu, edem (zlasti periferni)
{Not applicable in case of cartridge and pen pack.} 
{Ne pride v poštev v primeru kompleta vložka in peresnika}
Movymia must not be used with any other pen. 
Zdravila Movymia ne smete uporabljati z drugimi peresniki.
Read the patient information leaflet for Movymia cartridge provided separately. 
Preberite navodila za uporabo bolnikom za vložek Movymia, ki so priložena ločeno.
1 carton of Movymia cartridge (containing 1 cartridge) and 1 carton of Movymia Pen (containing 1 pen). 
Movymia komplet vložka in peresnika: 1 škatla vložka Movymia (z 1 vložkom) in 1 škatla Movymia Pen sistema (z enim peresnikom).
Each Movymia cartridge contains 28 doses of fixed 80 microlitres Movymia. 
Vsak od vložkov Movymia vsebuje 28 nespremenljivih odmerkov po 80 mikrolitrov zdravila Movymia.
If you become pregnant while using Movymia, Movymia should be discontinued. 
Če zanosite med uporabo zdravila Movymia, vam morajo zdravilo Movymia ukiniti.
Renal failure/impairment 
Nevretenčni zlomi zaradi krhkosti
• a compatible pen needle 
• združljivo iglo za peresnik
• Pull off the peel foil. 
• Odstranite zaščitno folijo.
Some patients may feel dizzy after injecting Movymia. 
Vpliv na sposobnost upravljanja vozil in strojev Nekateri bolniki lahko po injiciranju zdravila Movymia čutijo omotico.
1 cartridge 3 cartridges 
1 vložek 3 vložki
Movymia is supplied in a cartridge. 
Zdravilo Movymia je na voljo v napolnjenem vložku.
Movymia 20 micrograms/80 microliters solution for injection 
Movymia 20 mikrogramov/80 mikrolitrov raztopina za injiciranje
b p≤0.001 compared with placebo. 
p ≤ 0,001 v primerjavi s placebom Pomembnega zmanjšanja incidence zlomov kolka niso dokazali.
The expiry date on the cartridge label must always be checked before inserting the cartridge into Movymia Pen. 
Pred vstavljanjem vložka v peresnik Movymia Pen je treba vedno preveriti datum izteka roka uporabnosti zdravila na vložku.
Movymia 20 micrograms/80 microliters solution for injection Teriparatide 
Movymia 20 mikrogramov/80 mikrolitrov raztopina za injiciranje teriparatid
A significant reduction in the incidence of hip fractures has not been demonstrated. 
Vendar niso pokazali značilnega vpliva na razmerja zlomov.
Movymia must not be transferred to a syringe. 
Zdravila Movymia ne smete prenesti v injekcijsko brizgo.
How to store Movymia 
Shranjevanje zdravila Movymia
Do not use Movymia if you are pregnant or breast-feeding. 
Če ste noseči ali dojite, ne uporabljajte zdravila Movymia.
Always follow instructions provided below and on the back page when using the Movymia Pen. 
Pri uporabi Movymia Pen vedno upoštevajte spodnja navodila in navodila na zadnji strani.
New vertebral fracture (≥1) Multiple vertebral fractures (≥2) Non-vertebral fragility fractures 
Nov zlom vretenc (≥ 1)
Movymia 20 mcg/80 mcL injection teriparatide 
Movymia 20 µg/80 µl, injekcija teriparatid s.c.
• Carefully attach the outer needle cap on the pen needle. 
Odstranjevanje igle peresnika • Previdno pritrdite zunanji pokrovček igle na iglo peresnika.
Movymia cartridge 
KG Dengelsberg
LID FOIL 
POKROVČEK IZ FOLIJE
• Screw the pen needle clockwise onto the cartridge holder. 
• Iglo peresnika privijte v smeri urnega kazalca na nosilec vložka.
ANNEX III CONDITIONS OF THE MARKETING AUTHORISATIONS 
DODATEK III POGOJI DOVOLJENJ ZA PROMET Z ZDRAVILI
For the suspension to be lifted the Marketing Authorisation Holders would need to provide the National Competent Authorities with the following: 
Za preklic umika dovoljenj za promet morajo imetniki dovoljenj za promet z zdravili pristojnim nacionalnim organom predložiti:
Date of first authorisation: 21 February 2005 Date of latest renewal: 20 January 2010 
Datum prve odobritve: 21. februar 2005 Datum zadnjega podaljšanja: 20. januar 2010
Look out for any symptoms of infection or other symptoms such as: 
Bodite pozorni na kakršne koli simptome vnetja ali druge simptome, kot so:
 Tell your doctor if you are taking any of these medicines. 
 Obvestite zdravnika, če jemljete katero koli od teh zdravil.
 Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection 
 Nemudoma obvestite zdravnika o vsakem novem ali nenavadnem simptomu potem, ko ste prenehali z zdravljenjem, še posebej o simptomih, ki jih povezujete z okužbo s hepatitisom B.
• Although there are limited clinical data on the use of Truvada in pregnant women, it is not usually used unless absolutely necessary. 
• Čeprav je na voljo nekaj kliničnih podatkov o uporabi zdravila Truvada pri nosečnicah, se ga ponavadi ne uporablja, razen če je nujno potrebno.
Truvada with food and drink 
Zdravilo Truvada skupaj s hrano in pijačo
Therefore the use of Truvada may be considered during pregnancy, if necessary. 
Zato se lahko pretehta možnost uporabe zdravila Truvada med nosečnostjo, če je potrebno.
What Truvada is and what it is used for 
Kaj je zdravilo Truvada in za kaj ga uporabljamo
• palpitations, tremor or hyperactivity 
• palpitacije, tremor ali hiperaktivnost
• Whenever possible, Truvada should be taken with food. 
• Kadar je mogoče, je treba zdravilo Truvada jemati s hrano.
 If you notice these or any symptoms of inflammation or infection, get medical help immediately. 
 Če opazite te ali kakršne koli druge simptome vnetja ali okužbe, nemudoma poiščite zdravniško pomoč.
Taking Truvada with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including 
Jemanje zdravila Truvada z drugimi zdravili, ki lahko poškodujejo vaše ledvice: posebno pomembno je, da svojega zdravnika obvestite, če jemljete katero od sledečih zdravil:
• Talk to your doctor if you are intolerant to lactose (see Truvada contains lactose later in this section). 
• Z zdravnikom se posvetujte, če imate intoleranco za laktozo (glejte Zdravilo Truvada vsebuje laktozo v nadaljevanju tega poglavja).
 If you think you may have lactic acidosis, get medical help immediately. 
 Če menite, da bi lahko imeli laktacidozo, nemudoma poiščite zdravniško pomoč.
o Get tested for other sexually transmitted infections such as syphilis and gonorrhoea. 
o Testirajte se za druge spolno prenosljive okužbe, kot sta sifilis in gonoreja.
• Reminder of the key safety information regarding the use of Truvada for PrEP in adults and adolescents 
• opozorilo na ključne varnostne informacije v zvezi z uporabo zdravila Truvada za PrEP za odrasle in mladostnike;
People who do have HIV must take Truvada in combination with other drugs. 
Ljudje, ki imajo HIV, morajo zdravilo Truvada jemati v kombinaciji z drugimi zdravili.
Other medicines and Truvada 
Druga zdravila in zdravilo Truvada
• The importance of regular monitoring of renal function during Truvada therapy 
• pomembnost rednega spremljanja delovanja ledvic v času zdravljenja z zdravilom Truvada;
• Lactic acidosis (see Possible serious side effects) 
• laktična acidoza (glejte Možni resni neželeni učinki)
Each tablet contains 96 mg lactose monohydrate. 
Ena tableta vsebuje 96 mg laktoze monohidrata.
• this may cause the child to be tired or breathless 
• To lahko povzroči utrujenost ali zasoplost otroka.
Truvada should not be given to adolescents with existing kidney problems. 
Zdravila Truvada se ne sme dajati mladostnikom z obstoječimi ledvičnimi težavami.
The time to onset of protection after commencing Truvada is unknown. 
Čas do začetka zaščite po uvedbi zdravila Truvada ni znan.
• Reminder to attend scheduled clinic visits. 
• opozorila za načrtovane obiske pri zdravniku.
The most frequent adverse reaction reported in the Truvada group in the iPrEx study was headache (1%). 
Najpogostejši neželeni učinek, o katerem so poročali v skupini, ki je prejemala zdravilo Truvada v študiji iPrEx, je bil glavobol (1 %).
These may be signs of HIV infection: 
Možni znaki okužbe s HIV:
• If you have hepatitis B, it is especially important not to stop your Truvada treatment without talking to your doctor first. 
• Če ste okuženi s hepatitisom B, je še zlasti pomembno, da ne prenehate z zdravljenjem z zdravilom Truvada, ne da bi se prej posvetovali z zdravnikom.
• Know your hepatitis B virus (HBV) infection status before starting Truvada. 
• Ugotovite stanje okužbe z virusom hepatitisa B (HBV) pred začetkom jemanja zdravila Truvada.
• weakness beginning in the hands and feet and moving up towards the trunk of the body 
• oslabelost, ki se najprej pojavi v dlaneh in stopalih in se nato širi proti trupu
• If you become pregnant, or plan to become pregnant, ask your doctor about the potential benefits and risks of therapy with Truvada to you and your child. 
• Če zanosite ali načrtujete zanositev, se posvetujte z zdravnikom o možnih koristih in tveganjih zdravljenja z zdravilom Truvada za vas in vašega otroka.
Truvada should only be used in individuals with creatinine clearance (CrCl) < 80 mL/min if the potential benefits are considered to outweigh the potential risks. 
Zdravilo Truvada se sme uporabljati samo pri posameznikih z očistkom kreatinina (CrCl) < 80 ml/min, če se oceni, da morebitne koristi odtehtajo morebitna tveganja.
Truvada should only be used for pre-exposure prophylaxis as part of an overall HIV-1 infection prevention strategy including the use of other HIV-1 prevention measures (e.g. consistent and correct condom use, knowledge of HIV-1 status, regular testing for other sexually transmitted infections). 
Zdravilo Truvada se sme uporabljati samo za zaščito pred izpostavitvijo kot del splošne strategije za preprečevanje okužbe s HIV-1, vključno z uporabo drugih ukrepov za preprečevanje HIV-1 (npr. dosledna in pravilna uporaba kondomov, zavedanje statusa okužbe s HIV-1, redno testiranje za druge spolno prenosljive okužbe).
If you have kidney problems, your doctor may advise you to stop taking Truvada or, if you already have HIV, to take Truvada less frequently. 
Če imate ledvične težave, vam zdravnik lahko svetuje, da zdravilo Truvada prenehate jemati ali, če ste že okuženi s HIV, da zdravilo Truvada uporabljate manj pogosto.
Truvada is not always effective in preventing the acquisition of HIV-1. 
Zdravilo Truvada ni vedno učinkovito pri preprečevanju okužbe s HIV-1.
BMD Z-scores were not adjusted for height and weight. 
Z-vrednost MGK ni bila prilagojena za višino in telesno maso.
Therefore, the same problems may be seen if Truvada is administered with a third nucleoside analogue. 
Zato je možno, da se bodo enake težave pojavile pri jemanju zdravila Truvada s tretjim analogom nukleozidov.
Do not take Truvada to reduce your risk unless you are confirmed to be HIV negative. 
Zdravila Truvada ne jemljite za zmanjšanje tveganja, razen če je potrjeno, da ste HIV negativni.
Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system with approximately 70-80% of the dose excreted unchanged in urine following intravenous administration. 
Tenofovir se primarno izloča preko ledvic tako s filtracijo kot z aktivnim tubularnim transportnim sistemom, pri čemer se po intravenskem vnosu približno 70-80% odmerka izloči nespremenjenega z urinom.
Individuals over the age of 65 years are more likely to have decreased renal function, therefore caution should be exercised when administering Truvada to older people. 
Obstaja večja verjetnost, da je ledvična funkcija pri posameznikih, starejših od 65 let, zmanjšana, zato je pri dajanju zdravila Truvada starejšim ljudem potrebna previdnost.
If you feel dizzy while taking Truvada, do not drive and do not use any tools or machines. 
Če se vam v času zdravljenja z zdravilom Truvada pojavlja omotičnost, ne vozite avtomobila in ne upravljajte z orodji ali stroji.
If you have taken Truvada during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. 
Če ste zdravilo Truvada jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.